Partnering Opportunities

Welichem is seeking partnership to further develop WBI-5111 globally in the area of solid cancers.

WBI-5111 is a first-in-class small molecule anticancer drug candidate targeting carbonic anhydrase IX (CAIX) and currently under evaluating for the maximal tolerable dose in a phase I clinical study on late stage patients with solid cancers. Results are expected during the first half of year 2016.

Contact: Dr. Michael Lyle, PhD, VP, R&D; mlyle@welichem.com